Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient and disease characteristics in 8,039 patients in the QUEST-RA study in countries with a high (>24K USD) or low (<11K USD) GDP

From: Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study

  All patients
   Countries  
  Total High-GDP Low-GDP P valuea
Number 8,039 4,235 3,804  
Patient characteristics     
Female, percentage 80% 76% 85% < 0.001
Age in years, mean 55 58 52 < 0.001
Disease duration in years, mean 11 11 11 NS
Rheumatoid factor-positive, percentage 75% 73% 77% < 0.001
Erosive disease, percentage 63% 59% 67% < 0.001
Disease activity measures     
DAS28 (0 to 9.1), mean 4.4 3.7 5.2 < 0.001
ESR, median 25 18 33 < 0.001
SJC (0 to 28), median 2 1 4 < 0.001
TJC (0 to 28), median 4 2 9 < 0.001
Physician global (0 to 10), median 2.5 1.7 3.9 < 0.001
Patient self-report     
HAQ physical function (0 to 3), median 0.88 0.75 1.3 < 0.001
Pain VAS (0 to 10), median 4.1 3.2 4.7 < 0.001
Patient global VAS (0 to 10), median 4.2 3.2 4.8 < 0.001
Fatigue VAS (0 to 10), median 4.5 3.8 5.0 < 0.001
Psychological HAQ (0 to 3), mean 0.84 0.73 0.99 < 0.001
Treatment-related variables     
Number of DMARDs ever taken, mean 2.7 2.8 2.5 < 0.001
Biologics ever, percentage of patients 23% 31% 9.4% < 0.001
  1. aUnadjusted P values are presented. DAS28, disease activity score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GDP, gross domestic product; HAQ, Health Assessment Questionnaire; NS, not significant; QUEST-RA, Quantitative Standard Monitoring of Patients with Rheumatoid Arthritis; SJC, swollen joint count; TJC, tender joint count; USD, US dollars; VAS, visual analog scale.